Medtronic extravascular icd meets global pivotal clinical trial's safety and effectiveness endpoints

Late-breaking data presented at esc congress 2022 and simultaneously published in the new england journal of medicine confirms implant procedure safety and defibrillation success dublin and barcelona, spain , aug. 28, 2022 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced that its investigational ev icd™ system – a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins – achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global clinical trial. findings from the extravascular implantable cardioverter defibrillator (ev icd) pivotal study were presented as late-breaking science today at the european society of cardiology (esc) congress 2022 in barcelona and simultaneously published in the new england journal of medicine.
MDT Ratings Summary
Quant
MDT Quant Ranking
Sector
Industry
Quant Rating
Quant Score